Update: flutiform continues to impress
Following the successful April 2014 £112m capital raise and early repayment of the bonds, Skyepharma’s investment case now rests on the success of recent product launches. H114 results highlight the improving operational performance, especially the encouraging uptake for flutiform. The strengthened balance sheet enables a renewed emphasis on pipeline replenishment, with the licensing of a COPD technology platform notably promising. We raise our valuation from 260p a share to 326p.Skyland Petroleum is engaged in the licensing of copyright for feature films.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.